Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 4,239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

NCT05844293
View directory record Official record
Conditions
FXI
Interventions
FXI-GalNAc-siRNA, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Active, not recruiting Phase 3 Interventional

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

NCT05516992
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
SB-01 For Injection, Sham Needle
Drug
Lead sponsor
Spine BioPharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 31, 2026, 5:16 PM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Renal PK Study of LC350189

NCT04066712
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 200 mg
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

NCT01194830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT03296345
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions
Ketamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 31, 2026, 5:16 PM EDT
Recruiting Phase 1 Interventional

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

NCT07422675
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions
SER-252 (PEOZ-apomorphine), enFuse
Drug · Device
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969136
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 31, 2026, 5:16 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Navtemadlin, Navtemadlin Placebo
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Vallejo, California • Atlanta, Georgia • Savannah, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 5:16 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Changes in fMRI and Neurocognitive Function in Women With Pre-eclampsia

NCT03863639
View directory record Official record
Conditions
Pre-Eclampsia, Neurocognitive Dysfunction
Interventions
Neuroimaging Procedures, Neuropsychological Assessment Procedures
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

NCT05794139
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
NMD670, Placebo
Drug
Lead sponsor
NMD Pharma A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
View directory record Official record
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT02772965
View directory record Official record
Conditions
Pediatric Crohn's Disease
Interventions
Methotrexate, Sugar pill (placebo)
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 20 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Twelve Week Study of Supervised Mouth Rinse and Flossing

NCT04696536
View directory record Official record
Conditions
Healthy
Interventions
Colgate Cavity Protection Toothpaste, American Dental Association (ADA) Referenced Toothbrush, 5% Hydroalcohol Mouth Rinse, REACH Dental Floss, Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 31, 2026, 5:16 PM EDT
Recruiting Phase 2 Interventional

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of RR-HNK in OCD

NCT06575075
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
RR-HNK/Hydroxynorketamine, Placebo
Drug
Lead sponsor
Carolyn Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Terminated No phase listed Observational

A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.

NCT04763967
View directory record Official record
Conditions
Urinary Tract Infections in Children
Interventions
PedSCath Pediatric Urinary Catheter, Standard of Care
Device
Lead sponsor
Big Blue Biotech, Inc.
Industry
Eligibility
Up to 3 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 5:16 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Zasocitinib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
4 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Chula Vista, California • Fountain Valley, California • Hialeah, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

NCT02349295
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
59
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of AlphaBRAIN Administered Orally

NCT02739139
View directory record Official record
Conditions
Cognitive Functioning
Interventions
AlphaBrain
Dietary Supplement
Lead sponsor
Onnits Labs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 31, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 31, 2026, 5:16 PM EDT